1576PEfficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC

ConclusionsThe combination of bemcentinib and pembro was well tolerated and showed promising efficacy in previously treated IO-na ïve NSCLC pts, particularly in those with AXL positive disease, including PD-L1 negative pts. mOS of >  12 mos is favorable compared with historical references in the NSCLC second-line setting.Clinical trial identificationNCT03184571.Legal entity responsible for the studyBerGenBio ASA.FundingBerGenBio ASA.DisclosureJ.M. Trigo Perez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Blueprint Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimon...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research